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Antimicrobial resistance is a major global threat that calls for new antibiotics. Globomycin
and myxovirescin are two natural antibiotics that target the lipoprotein-processing enzyme,
LspA, thereby compromising the integrity of the bacterial cell envelope. As part of a project
aimed at understanding their mechanism of action and for drug development, we provide
high-resolution crystal structures of the enzyme from the human pathogen methicillin-
resistant Staphylococcus aureus (MRSA) complexed with globomycin and with myxovirescin.
Our results reveal an instance of convergent evolution. The two antibiotics possess different
molecular structures. Yet, they appear to inhibit identically as non-cleavable tetrahedral
intermediate analogs. Remarkably, the two antibiotics superpose along nineteen contiguous
atoms that interact similarly with LspA. This 19-atom motif recapitulates a part of the sub-
strate lipoprotein in its proposed binding mode. Incorporating this motif into a scaffold with
suitable pharmacokinetic properties should enable the development of effective antibiotics
with built-in resistance hardiness.
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As we move into an era of precision medicine and rationaluse of therapeutics, the prospect of having available bothbroad-spectrum and species-specific anti-infectives is
highly attractive. Early identification of the infectious agent and
treatment with a therapeutic that killed or attenuated the
pathogenic organism and no others would be the objective in the
case of species-specific drugs1. In so doing, some of the detri-
mental consequences of using broad-spectrum antibiotics that
include antibiotic-associated diarrhoea and thrush, where swaths
of the microbiota are thrown out of kilter, would ideally
be avoided2. Further, antibiotic resistance would be less of an
issue since just the one species would endeavour to respond to the
selective pressure. Anti-infective agents that reduce bacterial
virulence without exerting direct bactericidal activity (as anti-
biotics do) have the added advantage of reduced selective pressure
minimizing the risk of the emergence of resistant mutants.
One approach to species-specific drug development is through
structure-based drug design. This requires the structure of at least
one of the target orthologs, ideally at high resolution. However,
having the structure of orthologs from other pathogenic species
would prove extremely valuable. This is the goal of the current
study, focussed on the lipoprotein signal peptidase II, LspA
(abbreviations are included in Supplementary Table 1), an
enzyme involved in lipoprotein posttranslational processing in
bacteria (Fig. 1).
LspA is essential in Gram-negative bacteria, it has no mam-
malian equivalents and its active site is accessible to potential
drugs at the outer surface of the inner membrane3–5. These fea-
tures make it attractive as a drug target. Indeed, the natural
antibiotics, globomycin and myxovirescin (Fig. 1), which inhibit
LspA, are used in bacterial community internecine competition.
LspA is required for full virulence in Gram-positive bacteria6.
Since resistance development is less of an issue with virulence
factors, they are attractive drug targets7. A crystal structure of
LspA from the opportunistic human pathogen, Pseudomonas
aeruginosa (LspPae), in complex with globomycin is available5.
With a view to exploiting this for species-specific drug discovery,
a structure of the enzyme from another pathogen was sought. The
multi-drug resistant ESKAPE pathogens are a major threat to
public health8. Among this group, Staphylococcus aureus was
identified as a fitting target. Here we report high-resolution
crystal structures of LspA from methicillin-resistant S. aureus
(MRSA) (LspMrs) in complex with globomycin and with myx-
ovirescin A1 (hereafter myxovirescin). The structures confirm a
mechanism of action, which involves blocking the catalytic dyad
in this aspartyl protease. Interestingly, whilst globomycin
approaches from one side of the substrate-binding pocket, myx-
ovirescin does so from the other. Where these chemically and
structurally distinct antibiotics overlap in the complex provides a
blueprint for a drug development program. In combination with
the high-resolution structure of LspA from P. aeruginosa
(LspPae), these two structures set the stage for a campaign aimed
at species-specific as well as broad-spectrum drug discovery.
Results
Survival of the S. aureus lspA mutant in human blood. While
lspA is essential in Gram-negative bacteria such as E. coli and P.
aeruginosa, the lspA gene is not essential in Gram-positive
monoderm bacteria including S. aureus6,9. Previously, LspA-
deficient mutants of a methicillin-sensitive S. aureus (MSSA)
strain were shown to be attenuated in a mouse model of infection
and a signature-tagged mutagenesis screen in an MSSA back-
ground showed that disruption of lspA led to a loss of virulence in
a mouse model of bacteremia10,11. Here we generated an lspA
mutant of the community associated MRSA strain LAC. The lspA
mutant grew similarly to wild-type LAC in rich laboratory media,
showing that loss of LspA activity does not affect bacterial growth
in vitro (Supplementary Fig. 1a). To determine if LspA activity is
important for the survival of MRSA during human infection,
ex vivo infection studies were performed with whole human
blood. The lspA mutant had a reduced ability to survive in whole
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Fig. 1 Myxovirescin and globomycin target the lipoprotein posttranslational processing pathway. The pathway in Gram-negative bacteria employs the
prolipoprotein diacylglyceryl transferase, Lgt, to dagylate the pre-prolipoprotein, LspA to cleave off the signal peptide from the proliprotein and the
apolipoprotein N-acyltransferase, Lnt, to perform a final N-acylation step. LspA is inhibited by both antibiotics. Commonly used lipid substrates include
phosphatidylglycerol (PG) and phosphatidylethanolamine (PE). Non-protein products are glycerol-1-phosphate (G-P) and lyso-PE (LPE). Gram-positive
bacteria do not have the canonical Lnt. However, an Lnt-like activity in Gram-positives has recently been identified50. The blocking hydroxyl groups
common to both antibiotics that sit between the catalytic aspartates, thereby inhibiting LspA, are identified with red circles.
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human blood compared to the wild-type (Fig. 2a). The ability of
LAC lspA to survive in blood was restored by complementation
with the lspA gene on a multi-copy plasmid (LAC lspA
(pALC2073::lspA). These results show that LspA activity is
important for the survival of MRSA in human blood. As a con-
trol, the same strains and mutants were incubated in fresh plasma
from the same blood donors. There was no reduction in the
ability of the lspA mutant to grow in human plasma (Fig. 2b)
under the same conditions. This indicates that the lspA mutant
has a reduced ability to survive killing by phagocytes in human
blood rather than having a growth defect under the conditions
used. These findings identified the LspA enzyme as an attractive
target for treatment of MRSA infection. In support of a structure-
based drug design campaign we next sought to determine a high-
resolution X-ray crystal structure of LspA from MRSA (LspMrs).
LspMrs-globomycin complex structure. Recombinant LspMrs
was produced and purified using in vivo methods of expression
(Supplementary Fig. 2). The enzyme is 163 residues long and was
hexahistidine-tagged. It was shown to be active using a gel-shift
assay with a recombinant prolipoprotein, inhibitor of cysteine
protease (proICP), as substrate (Table 1, Supplementary Figs. 3a
and 4, Supplementary Table 2). LspMrs was also assayed by
fluorescence resonance energy transfer (FRET) using a single
molecule FRET lipopeptide (Supplementary Figs. 3b and 5,
Supplementary Table 2). Under optimized conditions, the
enzyme, at a concentration of 0.3 μM, had an estimated apparent
Km of 47 μM and Vmax of 2.5 nmol/(mgmin), as determined by
FRET assay. The corresponding values for LspPae were 10 μM
and 107 nmol/(mgmin) at an enzyme concentration of 0.1 µM,
suggesting that the S. aureus ortholog is a slower acting peptidase
with a lower substrate affinity than its P. aeruginosa counterpart
(see Supplementary Discussion). The purified enzyme from both
organisms was inhibited by globomycin with IC50 values
approaching the enzyme concentration used for assay (Supple-
mentary Fig. 6, Supplementary Table 3). This is consistent with
tight binding inhibition12,13 (Supplementary Discussion). When
proICP was used as substrate, the IC50 of LspPae for globomycin
was 0.64 μM at an enzyme concentration of 0.5 μM, again con-
sistent with tight binding. However, for LspMrs the value was
171 μM at an enzyme concentration of 0.5 μM (Supplementary
Fig. 4, Table 1). The latter insensitivity to globomycin with a
lipoprotein substrate may reflect the ortholog’s sequence and
structure. It may also have to do with the substrate identity and
concentration used in the assay, as discussed (Supplementary
Discussion).
Initial attempts at crystallizing recombinant, hexahistidine-
tagged LspMrs in its apo- and globomycin bound forms using the
in meso method, as implemented with LspPae, were not
successful. However, crystals and a structure to 1.92 Å resolution
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Fig. 2 Survival of the S. aureus lspAmutant in human blood and plasma. a S. aureus LAC and the lspAmutant were incubated in whole blood and b plasma
from healthy human blood donors. LAC corresponds to wild-type S. aureus, LAC lspA to the inactive mutant, LAC lspA (pALC2073) to the mutant carrying
the empty multicopy plasmid and LAC lspA (pALC2073::lspA) to the mutant carrying the multicopy plasmid containing the lspA gene. Total viable counts
were determined for the initial inoculum (T0) and blood and plasma samples 3 h post-inoculation (T3). The percentage of bacterial survival was determined
by dividing the T3 count × 100 by the T0 count. Each data point represents a different blood donor. Statistical significance was determined using one-way
ANOVA+ Bonferroni’s Multiple Comparison Test. ***P < 0.0001. Source data are provided as a Source Data file.
Table 1 Effect of antibiotics on peptidase activity of LspA
constructs determined by gel-shift assay.
Construct Relative
activity (%)a
IC50 (µM)c,d,e
Globomycin Myxovirescin
LspPae WT 133b 0.64 ± 0.16 1.09 ± 0.34
LspMrs WT 100 170.7 ± 0.64 0.16 ± 0.00
N52A 7 1.23 ± 0.59 – f
N52Q 71 2.43 ± 0.34 0.29 ± 0.08
G54A 113 1.78 ± 0.25 0.57 ± 0.01
G54P 0 ND ND
R110A 0 ND ND
R110K 50 1.73 ± 0.10 0.40 ± 0.03
D118N 0 ND ND
N133A 3 ND ND
N133Q 3 ND ND
D136N 0 ND ND
Source data are provided as a Source Data file
aThe values shown are based on product formed after 30minutes of reaction
bUnder initial rate conditions (the first 5 min of reaction), the relative activity value is closer to
300% (see Supplementary Fig. 8). After 30 min of reaction, the relative activity is 133%
cIC50 values are shown as the average (±standard deviation) of duplicate measurements
dFor reference purposes, minimum inhibitory concentration (MIC) values for globomycin acting
on P. aeruginosa and S. aureus were >100 μg/mL (152 μM)51. The most potent globomycin
analogue included in that study had corresponding MIC values of >100 μg/mL (152 μM) and
6.3–12.5 μg/mL (9.6–19.1 μM)51
eMIC values for myxovirescin A acting on E. coli has been reported at 1 μg/mL (1.6 μM)39
fThe signal was too weak for quantification using Image Lab software
ND not determined
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were obtained for the LspMrs-globomycin complex when the tag
was removed (Fig. 3a and Supplementary Fig. 2, Table 2). With a
sequence identity between LspMrs and LspPae of 31%, it was not
surprising that the structures of the two complexes were similar
with a Cα r.m.s.d. of 0.713 Å over 155 residues. The enzyme
consists of four transmembrane helices (H1-H4) with the
catalytic dyad aspartates, Asp118 and Asp136, towards
the membrane’s outer surface. Extending away from the catalytic
dyad and to one side of the bundle of transmembrane helices is
the β-cradle, a hemi-cylindrically shaped sheet that sits on the
membrane. It is proposed to accommodate the stretch of residues
to the C-side of the LspA cleavage site in lipoprotein substrates.
An extracellular loop (EL) between strand 2 (S2) in the β-cradle
and H2 sits above the substrate binding pocket in which resides
globomycin. Globomycin, a 19-member cyclic depsipeptide that
includes five amino acids (g.Ser, g.Thr, g.Gly, g.Leu g.Ile; the g
refers to globomycin) and an α-methyl-β-hydroxy nonanoate
(Fig. 1 and Supplementary Fig. 3c), inhibits LspA by lodging the
β-hydroxyl of its g.Ser between the catalytic aspartates. Our
interpretation is that the antibiotic acts as a non-cleavable
tetrahedral intermediate analog as has been proposed for many
inhibitors of other aspartyl proteases14. The 14 highly conserved
residues (Asp21, Lys25, Asn52, Gly54, Gly102, Asn106, Asp109,
Arg110, Val116, Asp118, Phe132, Asn133, Ala135, Asp136) in
LspMrs cluster around globomycin in the active and
substrate binding sites in ways that make good biochemical
sense (Supplementary Fig. 7), as described for LspPae5. Site-
directed mutagenesis supports the view that the catalytic dyad
residues are Asp118 and Asp136 (Table 1). Contacts between
globomycin in LspMrs and in LspPae are very similar
(Supplementary Table 4)5.
The prolipoprotein substrate of LspA consists of an N-
terminal signal peptide of about twenty amino acids followed by
the consensus lipobox [L(VI)−3-A(STVI)−2-G(AS)−1-C*+1]15
and the functional C-terminal protein domain (Supplementary
Fig. 3a). LspA cleaves between the G and the C* in the lipobox
where C* represents a diacylglyceryl (DAG)-modified (dagy-
lated) cysteine. The signal peptide is assumed to be helical and
to be accommodated in the membrane in the space created by
the orthogonally packed H2, H3 and H4 in LspA (Supplemen-
tary Fig. 9). The lipobox is proposed to take the form of an
extended peptide with the scissile bond between Gly and Cys*
next to the catalytic dyad aspartates. It is the lipobox sequence
that the g.Leu-g.Ile-g.Ser in globomycin is assumed to mimic.
The acyl chains of the DAG in C* have been modeled to situate
below the β-cradle (Supplementary Fig. 9). Evidence in support
of this model comes from the location of monoolein lipid
molecules in the crystal structure that derive from the cubic
mesophase in which crystallization was performed (Supple-
mentary Fig. 10)5.
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Fig. 3 Structures of LspMrs in complex with globomycin and with myxovirescin. a, b Views from the membrane into the binding pocket containing
globomycin and myxovirescin, respectively. c Detailed view of the blocking hydroxy group (6-OH) of myxovirescin interacting with the catalytic aspartate
residues. d–f Comparison of myxovirescin and globomycin in the binding pocket of LspMrs. Superposed protein structures are shown in the background
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pocket is shown in e. Because myxovirescin has a complicated bent ovoid shape (Supplementary Fig. 11) it is impossible to find a single orientation where
all of its non-hydrogen atoms are visible. For a fuller appreciation of myxovirescin’s molecular shape, the reader is referred to the Protein Data Bank record
(PDB ID, 6RYP). In b, the C-terminal residues K157, K158, E159, K160, E161, V 162 and K163, which extend into the cytoplasm as a helix/coil, have been deleted
for a more uniform comparison with a where these residues are disordered. Distances are shown in ångströms as dashed lines.
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Together, these structural and biochemical data show that
LspA from MRSA, a Gram-positive bacterium, is a close ortholog
of its counterpart in the Gram-negative P. aeruginosa. One noted
difference however is in the sensitivity of LspA in the two
organisms to globomycin when assayed by the gel-shift method
with proICP as substrate (Table 1).
LspMrs-myxovirescin complex structure. Myxovirescin, also
known as antibiotic TA, megovalicin or M-230B, is a 28-
membered macrolactam lactone16 (Fig. 1 and Supplementary
Fig. 3c). It is an inhibitor of LspA and a potential broad-spectrum
antibiotic with desirable adhesive properties. Myxovirescin has
been used in clinical trials for the treatment of plaque and gin-
givitis17 and has been proposed for use in limiting infection rate
associated with indwelling catheters18. Despite both myxovirescin
and globomycin being LspA inhibitors, their chemical makeup
(Fig. 1) and the pathways used for in vivo synthesis are entirely
different. Myxovirescin is a secondary metabolite produced by
Myxococcus xanthus while globomycin is a product of Strepto-
myces hagronensis19,20. Other than being cyclic and containing
hydroxyl, ester and amide moieties the two antibiotics are che-
mically distinct. Indeed, attempts ‘by eye’ failed to predict the
binding pose of myxovirescin observed in the final crystal
structure based on that for the LspMrs-globomycin complex
(Fig. 3a). In FRET and gel-shift assays, myxovirescin was shown
to be a potent inhibitor of LspMrs and LpsPae (Supplementary
Figs. 4 and 6, Table 1).
Despite extensive efforts, attempts at generating a crystal
structure of myxovirescin in complex with LspPae failed.
However, when combined with LspMrs, crystals and a structure
of the complex to 2.30 Å resolution were obtained by the in meso
method using monoolein as the host lipid (Fig. 3b and Table 2).
Overall, the structure of the protein in the myxovirescin complex
is very similar to that of the complex with globomycin.
Differences were noted at the C-terminus that was fully formed
as an extended helix in the myxovirescin complex but was
disordered, and without useful electron density in the globomycin
complex. Another important difference at the EL is
described below.
Differences and similarities in the complex structures. What
came as a surprise when the structures of LspMrs in complex with
globomycin and myxovirescin were compared was the finding
that the two antibiotics interact with the enzyme by associating
with opposing sides of the substrate-binding pocket (Fig. 3d–f).
However, at the catalytic dyad, which presumably is where it
matters, both engage identically. Looking into the binding pocket
from the membrane plane, globomycin binds with its g.Ser
hydroxyl lodged between the catalytic dyad aspartates and with
the rest of the depsipeptide ring bound to the right side of the
pocket neatly tucked in under a retracted EL (Fig. 3a). By con-
trast, myxovirescin binds with its macrocycle docked on the left
side of the pocket with the EL extended out and over the ring
(Fig. 3b). However, despite this marked difference in docking
mode and approach to the active site, the 6-OH of myxovirescin
wedges firmly between the two catalytic aspartates inhibiting the
enzyme (Fig. 3c), just like globomycin, as a non-cleavable
Table 2 Data collection and refinement statisticsa.
LspMrs-
globomycin (6RYO)
LspMrs-
myxovirescin (6RYP)
Data collection
Space group P3221 P6122
Cell dimensions
a, b, c (Å) 52.3, 52.3, 135.9 54.2, 54.2, 317.5
α, β, γ (°) 90, 90, 120 90, 90, 120
Beamline SLS-X06SA SLS-X06SA
Wavelength (Å) 0.92003 1.0
Resolution (Å) 45.26–1.92 (2.23–1.92)b 46.40–2.30 (2.36–2.30)
No. of reflections
(total/unique)
33,655/7,051 199,005/23,038
Rmeas 0.17 (1.38) 0.14 (2.79)
I/σI 7.00 (1.80) 7.69 (0.90)
Completeness (%) 86.20 (62.50)c 99.9 (100)
Multiplicity 4.80 (3.70) 8.63 (8.90)
CC1/2 0.99 (0.47) 0.99 (0.22)
Refinement
Resolution (Å) 45.26–1.92 46.40–2.30
Reflections 7046 23,038
Rwork=Rfree 0.25/0.28 0.25/0.28
R.m.s. deviations
Bond lengths (Å) 0.002 0.001
Bond angles (°) 0.498 0.372
No. of atoms
Protein 1232 1287
Globomycin or
Myxovirescin
46 44
Other ligandsd 242 176
Water 28 12
B-factor
Protein 36.78 68.15
Globomycin or
Myxovirescin
20.87 75.61
Other ligandsd 58.91 100.05
Water 29.36 75.49
Ramachandran Plot
Favored (%) 97.39 98.15
Allowed (%) 2.61 1.85
Outliers (%) 0 0
MolProbity
Clashscore
7.87 1.32
aData processing statistics are reported with Friedel pairs merged for 6RYO and Friedel pairs
separated for 6RYP
bValues in parentheses are for the highest resolution shell
cEllipsoidal completeness, as defined by autoPROC/STARANISO, is referred to here
dOther ‘ligands’ include monoolein, glycerol, PEG, SO42− and Zn2+
a b
c d
e
Fig. 4 Overlay of myxovirescin and globomycin in the LspMrs complex
structures. The superpose identifies atom positions along the ‘spine’ that
are common to the two antibiotics. a View from the membrane into the
active site. b View from the active site. c View along the spine (bottom)
from the extracellular space. d View along the spine (bottom) from the
cytoplasm. Myxovirescin and globomycin are shown with carbon atoms
colored cyan and yellow, respectively. The blocking hydroxyl in
myxovirescin and globomycin is shown in magenta and is marked with a
black arrow. A dashed line in a, b is included to guide the eye in locating the
spine feature. e With a common spine and the macrocycles splayed apart,
the image of the two superposed antibiotics gives the impression of a
butterfly with outstretched wings.
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tetrahedral intermediate analog. Indeed, the 6-OH of myxovir-
escin and the β-OH of g.Ser, hereafter referred to as blocking
hydroxyls, superpose to within 0.8 Å in the two complex struc-
tures (Fig. 3a, c). Given the disparate natures and biosynthetic
origins of the two antibiotics, this agreement in the placement of
the blocking hydroxyls is remarkable.
The similarities do not end there. Tracking along the
myxovirescin molecule from the 6-OH to the [-4NH-3C(O)-]
amide linkage (Supplementary Fig. 3c) we find the latter
hydrogen bonded to the catalytic Asp136 and to Arg110. The
exact same interaction exists between the g.Ser-to-g.Ile amide
linkage in globomycin and Asp136 and Arg110 in LspMrs
(Supplementary Table 4). Indeed, the sequence of six consecutive
atoms from 6-OH to 3-C(O) in the myxovirescin complex
superpose with identical atoms in the globomycin complex
(Fig. 4). This impressive overlap extends for another thirteen
contiguous atoms to 23-C in myxovirescin which comes close to
aligning with 4-C in globomycin. The correspondence of all
nineteen, what we refer to as spine atoms, is shown in Fig. 5.
Beyond the spine termini at 6-C and 23-C in myxovirescin and
4-C and 13-C in globomycin, the two rings diverge and splay
apart with the myxovirescin ring oriented to the left and the
globomycin ring to the right of the substrate binding pocket
(Figs. 3d, f and 4a).
It is interesting to see globomycin partition to one half of the
substrate-binding pocket while myxovirescin partitions to the
other. Both macrocycles have polar and apolar sides. For the most
part, it is the former that overlap along the spines in the complex
structures (Fig. 5). The apolar parts extend away from the spine
and to the left and right halves of the substrate-binding pocket
(Fig. 4a). In myxovirescin, the apolar part situates partly below
the overarching β-cradle. This is reminiscent of the proposed
binding mode for the acyl chains of the DAG in the
prolipoprotein substrate (Supplementary Fig. 9). In the case of
globomycin, the g.Ile and g.Leu apolar side chains and the
nonanoate acyl chain extend from the bottom of the ring. The
latter wraps around the membrane embedded portion of H2
below the apolar surface of the EL. Thus, the two antibiotics
appear to have evolved to mimic different features of the natural
substrate for better association with the substrate binding surfaces
of the enzyme to properly position their blocking hydroxyls
between the catalytic dyad residues.
With a common spine of nineteen atoms and the macrocycles
splayed apart as described, the image of the two superposed
antibiotics gives the impression of a butterfly with outstretched
wings (Fig. 4e). The body of the butterfly is the spine of atoms
‘shared’ by both antibiotics; the two divergent macrocycles and
blocking hydroxyls correspond to the butterfly wings and head,
respectively. Relatedly, of note is the similarity between the
‘business end’ of the spines that engages with the catalytic dyad
and the hydroxy-ethylamine isostere developed as the active
pharmacophore in several FDA approved HIV-1 (aspartyl)
protease inhibitors (Fig. 5b)14.
The plane of the globomycin ring is relatively flat. By contrast,
in complex with LspMrs, myxovirescin assumes the shape of an
ovaloid disc bent at its broad end (Figs. 3 and 4, Supplementary
Fig. 11). The flat face and bent portions of the disc include ring
members 1–16 and 17–28, respectively. The former faces the
active site positioning the blocking 6-OH between the catalytic
dyad residues. The latter extends orthogonally away from the
surface of the substrate-binding pocket and toward the apolar
recesses of the membrane. Interestingly, the overlap between
globomycin and myxovirescin includes both upright and bent
sides of the macrolactam ring (Fig. 4). Equally interesting is the
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Fig. 5 Atoms in globomycin and myxovirescin with common positions in the complex structures. These are referred to in the text as ‘spine atoms’.
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overlap between the apolar side chain of g.Ile and the propyl
moiety of myxovirescin. In the former, the chain points out of the
globomycin ring, in the latter it points into the macrolactam ring
(Fig. 4a and supplementary fig. 3c). The symmetry in the
superposed antibiotic structures extends to the long acyl chain in
globomycin which is matched by the apolar sequence of atoms
(ring atoms 12–23) in myxovirescin to which is attached an
outstretched ethyl group (Supplementary Fig. 3c). The impression
given by these apolar regions is that they contribute to stabilizing
the interaction between the antibiotics and the enzyme through
shape and hydrophobic complementarity with different mem-
brane integral parts of the protein.
All fourteen of the highly conserved residues in LspA are
similarly poised in the globomycin and myxovirescin complex
structures, with the exception of Gly54 which facilitates the
flexibility of the extra-cytoplasmic loop, as discussed below. Half
of these are in hydrogen bonding distance to either antibiotic
(Supplementary Fig. 12, Supplementary Table 4) along the ring
spine referred to above. One of the conserved residues, Asn52, is
particularly interesting. Site-directed mutagenesis attest to its
importance in LspA function (Table 1). It interacts with both
antibiotics where they have just splayed apart in the superpose at
the extra-membrane entrance to the active site (Supplementary
Fig. 13). Its Nδ2 forms a hydrogen bond with the 8-OH in
myxovirescin and with the γ-OH on g.Thr in globomycin. Asn52 is
part of the β-cradle and is held in place by hydrogen bonds to the
backbone amide and carbonyls of highly conserved Val116 which
also is in the β-cradle. It seems remarkable that these two entirely
different antibiotics have evolved to exploit for binding in very
different ways the same conserved residues in LspA presumably to
the same ends of tightly binding to and inactivating the enzyme.
EL flexibility. It was noted that an important difference between
the structures of LspMrs with myxovirescin and globomycin was
at the EL, a sequence of 11 residues from Asn53 to Lys63. In the
globomycin complex, the loop includes a half-turn helix from
which extends conserved Trp57. The tryptophan reaches over the
globomycin molecule and secures it in place against one side of
the substrate-binding surface of the enzyme by hydrogen bond-
ing. In the myxovirescin complex, the loop has unfolded fully and
extends deeper into the substrate-binding pocket enabling the
benzene ring of Trp57 to contact the macrocycle locking it in
position against the opposite side of the pocket surface (Supple-
mentary Fig. 14). Thus, EL flexibility is key to effective globo-
mycin and myxovirescin binding to LspA. It seems unlikely that
LspA evolved this loop pliability unless it furthered its own ends,
one of which is to process lipoproteins. Given the considerable
number of substrate lipoproteins LspA must process (175 in Pae,
67 in Mrs), EL flexibility may well reflect a certain level of
necessary substrate promiscuity. Gly54 is the second residue in
the loop and is expected to play a role in flexibility. Indeed,
mutating it to Pro, a residue known to limit mobility, fully
inactivates the enzyme with lipoprotein substrate (Table 1).
Together these data highlight how globomycin and myxovirescin
have exploited functional loop flexibility to their respective ends
through convergent evolution.
Discussion
The fact that both globomycin and myxovirescin interact closely
with many of the highly conserved residues in LspA (Supple-
mentary Figs. 7 and 12) raises an interesting point concerning
their resistance hardiness. Mutations in these residues in isolation
that weaken the enzyme’s interaction with the antibiotics might
be expected to reduce antibacterial potency. At the same time
however, mutating conserved residues will compromise the host
bacterium as a result of inactivating, destabilizing or attenuating
expression of LspA. No competitive advantage would be gained
by doing so. It appears therefore that globomycin and myxovir-
escin may have evolved to be ‘resistance-proof’ and, in principle,
should be attractive as therapeutic agents or leads. It can be
difficult and in some cases impossible to test this hypothesis of
resistance hardiness by means of site-directed mutagenesis where
both potency and affinity are monitored based on enzyme
activity. However, a number of such mutants have been prepared
and their peptidase and antibiotic sensitivities have been mea-
sured (Table 1). Interestingly, in all cases the IC50 for globomycin
determined using a lipoprotein substrate dropped compared to
wild-type values. It would appear that other interactions are
called into play to compensate for the changes introduced in the
mutant constructs that make it an even more potent inhibitor.
Crystal structures of these mutants in complex with globomycin
would shed light on this proposal and may prove useful in drug
design. Nonetheless, it makes sense that lessons in resistance
hardiness and longevity provided by nature should be applied to
structure-based drug discovery strategies. Specifically, this would
take the form of incorporating into the design of therapeutics
interactions between the lead compound and conserved residues
in the target protein. Useful information in support of drug
design might also derive from a study of the LspA enzymes in the
organisms that produce globomycin and myxovirescin.
Given that the organisms responsible for producing globo-
mycin and myxovirescin come from different lineages of bacteria,
the two antibiotics provide a convincing example of convergent
evolution. Globomycin is produced by at least five Streptomyces
species20 belonging to the phylum actinobacteria. Streptomyces
are aerobic, Gram-positive, immotile filamentous bacteria con-
taining branching mycelia and aerial hyphae where chains of
spores form in a manner that resembles most filamentous fungi21.
By contrast, Myxococcus xanthus, the source organism for myx-
ovirescin, belongs to the phylum proteobacteria, and is a Gram-
negative bacteria, known for its social behaviour, gliding motility,
and fruiting body and myxospore formation22. Both bacterial
species are found in soil, a microbe-rich environment, where they
use the products of secondary metabolism for defence. Otherwise,
these two antibiotic producing microorganisms have little in
common. Indeed, they are as far apart in the kingdom bacteria as
can be. All bacterial species contain the lspA gene for purposes of
primary metabolism. However, there are only two bacterial gen-
era, Streptomyces and Myxococcus, known to produce molecules
that target LspA. There is no evidence of an ancestral molecule
targeting the LspA active site.
Convergent evolution refers to the acquisition over time of
similar form and function in organisms of distinct genetic origin.
In the current example, that commonality finds expression in two
entirely unrelated secondary metabolites. These have been crafted
through the action of profoundly different multistep pathways in
different bacterial species to target identically a specific catalytic
dyad in the lipoprotein processing enzyme, LspA. Myxovirescin is
synthesized from short chain carboxylates by a polyketide syn-
thase19. By contrast, a giant nonribosomal peptide synthetase is
likely implicated in globomycin synthesis. Remarkably, the two
antibiotics have achieved potency and specificity through a cri-
tical hydroxyl group that extends from profoundly different
molecular scaffolds (Fig. 1). In myxovirescin, the scaffold is a
macrolactam lactone. In globomycin, it is a cyclic depsipeptide.
Therefore, the biosynthetic machineries in Myxococcus and
Streptomyces have been able to fabricate molecular features in
myxovirescin and globomycin, respectively, to mimic similar as
well as distinct characteristics of the natural prolipoprotein sub-
strate and the tetrahedral transition state intermediate it pre-
sumably forms during proteolytic cleavage.
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Other examples of natural antibiotics that may have emerged
through convergent evolution include rifampicin and sorangicin,
which target the β subunit pocket in RNA polymerase (RNAP)23
and ripostatin and corallopyronin which bind to the switch
region of RNAP24.
As noted, nature has evolved globomycin and myxovirescin to
target lipoprotein posttranslational processing at the peptidolytic
step catalysed by LspA. The active site in the enzyme, consisting
of catalytic dyad aspartates, is specifically targeted by both. Each
includes a hydroxyl group suitably disposed for placement
between the dyad residues and mimicking, in a non-cleavable
analog, the hydroxyl of the putative tetrahedral intermediate. In
the structures of LspA complexed with globomycin and with
myxovirescin these blocking hydroxyl oxygens superpose to
within 0.8 Å of one another (Fig. 5). This precise placement
undoubtedly reflects a multitude of molecular features in the two
antibiotics. These include a common spine of 19 contiguous
atoms and surrounding macrocycles that target, respectively, the
proposed signal peptide and diacylglyceryl binding surfaces
in LspA.
Clearly, the 19-atom long spines in globomycin and myx-
ovirescin are proven and effective and can be viewed as natural
pharmacaphores. Their chemical composition and structure can
be used to inform drug design and discovery efforts with a view to
producing more potent broad spectrum as well as species-specific
antibiotics. In the case of globomycin and myxovirescin, both are
macrocycles and it may be that this feature must be retained in
related newly produced therapeutics. However, the scaffold used
to make the ring can be optimized separately for pharmacokinetic
properties and for outer membrane permeability when targeting
Gram-negative pathogens. Provided the synthesis can be realized
and the product is not too bulky, it might be worth generating a
bicyclic compound inspired by the superposition of the two
antibiotics in the complex structures. One ring in the bicycle
would mimic that in globomycin, the other the scaffold in
myxovirescin (related to our suggestion to use the binding poses
of globomycin and myxovirescin in LspA to inform the genera-
tion of a more effective bicyclic compound, the recently dis-
covered natural antibiotic darobactin is bicyclic, consisting of two
fused peptide rings25). This would then combine in the one new
chemical entity features that target simultaneously the active site
as well as the proposed signal sequence and diacylglyceryl binding
surfaces of the substrate-binding pocket delivering high potency
and specificity. A long-term goal of the current project is to
explore these options along with structures of complexes with
orthologs from pathogenic and benign species to aid in tailoring
antibiotics that are either broad spectrum or species-specific in
their application.
We have shown that LspA is an ideal target for anti-infective
agents as it is required for the survival of MRSA under physio-
logically relevant conditions in human blood. Thus even in bac-
terial species where LspA is not essential there is potential for
therapeutic benefit using drugs that target LspA.
Methods
Bacterial strains and mutants. The S. aureus LAC strain used here is an ery-
thromycin sensitive derivative of the USA300 MRSA strain LAC (a gift from A.
Horswill, University of Colorado)26. An lspA-deficient mutant of LAC was gen-
erated by phage transduction of the lspA::Tn cassette from the NEBRASKA library
JE2 strain27 using ɸ85. Resulting transductants were selected on erythromycin-
containing agar and the presence of the transposon was confirmed by carrying out
the polymerase chain reaction on genomic DNA using primers that anneal
upstream and downstream of the lspA gene and by DNA sequencing of the
polymerase chain reaction product. LAC lspA was phenotypically indistinguishable
from LAC in terms of growth profile in tryptic soy broth (TSB) (Supplementary
Fig. 1a) and haemolysis patterns on sheep blood agar (Supplementary Fig. 1b).
Complementation of the lspA mutant was achieved by cloning the lspA gene
from LAC into the expression plasmid pALC207328 between EcoRI and KpnI
restriction sites to generate pALC2073::lspA. The lspA gene was amplified using the
LspA Forward (5′-GCAGGTACCATTGGAGGAACGAAAATGCAC-3′) and
LspA Reverse (Lsp, 5′-GCCATGAATTCCTCCATTACTTAACCTCCTTCTCC-
3′) primers. The mutant was transformed with plasmid DNA using
electroporation. Empty plasmid pALC2073 was introduced into the mutant to
serve as a control.
Survival and growth in human blood and plasma. Human blood was obtained
from healthy volunteers between 20 and 40 years of age. Ethical approval for the
use of human blood was obtained from the Trinity College Dublin Faculty of
Health Sciences ethics committee.
Freshly drawn blood was collected in tubes containing the anti-coagulant
hirudin (Refludan, Pharmion). The plasma fraction was obtained by centrifugation
of the blood at 4,000 × g for 10 min. To quantify survival of S. aureus in human
blood and plasma the method described by O’Halloran et al.29 was followed.
Briefly, S. aureus was grown in TSB overnight at 37 °C for 16–18 h. The bacteria
were diluted into RPMI-1640 medium to a final density of ca. 1 × 104 CFU/mL
and 25 μL of this was added to 475 μL of blood or plasma. Tubes were incubated at
37 °C with gentle rocking, and after 3 h serial dilutions were plated in triplicate to
determine the CFU/mL of viable bacteria and the percentage survival of the
original inoculum was determined.
Expression and purification for structure determination. The recombinant
construct used in this study was the full length, wild-type LspA from methicillin
resistant Staphylococcus aureus (strain MRSA252, LspMrs). The sequence of LspA
from MRSA252 differs from the LAC sequence at residue 111 only (valine in
MRSA252, isoleucine in LAC). It consisted of an N-terminal MG sequence fol-
lowed by a hexahistidine-tag, the tobacco etch virus (TEV) protease spacer
sequence DYDIPTT, the TEV protease cleavage site ENLYFQ/G, an AH linker
sequence and the lspA gene. The gene, codon optimised for E. coli expression using
the OptimumGene™ program provided on the GenScript web server (www.
genscript.com), was commercially synthesised (GenScript) and sub-cloned into the
expression vector pET28a using the restriction sites NdeI and XhoI. The pET28a-
lspA recombinant plasmid was transformed into chemically competent E. coli C43
(DE3) (Lucigen) cells. Cells were grown in TB media supplemented with 50 μg/mL
kanamycin (Melford) at 37 °C to an optical density at 600 nm (OD600) of 0.5–0.6
and gene expression was induced with 1 mM isopropyl β-D-1-
thiogalactopyranoside at 30 °C and 180 rpm for 18 h. Cells were harvested by
centrifugation at 6000 × g for 15 min at 4 °C. Cells were either used immediately for
purification or stored at −70 °C for a maximum of 2 months.
For purification, cells were re-suspended in 1 g/mL ice-cold Buffer A (50 mM
MES/NaOH pH 6.15, 150 mM NaCl, 10%(v/v) glycerol). A single cOmpleteTM
Protease Inhibitor Cocktail tablet (Roche) was added per 50 mL of re-suspended
cells. Cells were lysed by passing three times through a high-pressure homogenizer
(Emulsiflex-C5, Avestin®) at 1,500 bar and 4 °C. Cell debris was removed by
centrifugation at 25,000 × g for 25 min at 4 °C. The supernatant was ultra-
centrifuged at 150,000 × g for 1.5 h at 4 °C. The membrane pellet was re-suspended
in 100 mL Buffer A and 1%(w/v) LMNG (Anatrace). Solubilisation was carried out
for 18 h at 4 °C on a rotor circulating at 10 rpm. Unsolubilised material was pelleted
by ultra-centrifugation at 100,000 × g for 1 h at 4 °C. The supernatant was
supplemented with 20 mM imidazole and incubated with 5 mL Ni-NTA Superflow
resin (Qiagen) for 1 h at 4 °C on a rotor circulating at 20 rpm for immobilised
metal-ion affinity chromatography (IMAC) purification. The resin was transferred
to a 100 mL Bio-Rad Econo Column (4 cm diameter) and was washed with 100 mL
Buffer B (50 mM MES/NaOH pH 6.15, 300 mM NaCl, 10%(v/v) glycerol, 0.02%
(w/v) LMNG, 40 mM imidazole). Bound protein was eluted with 20 mL Buffer C
(50 mM MES/NaOH pH 6.15, 300 mM NaCl, 10%(v/v) glycerol, 0.02%(w/v)
LMNG, 300 mM imidazole). In all, 1 mL fractions were collected and protein
concentration was determined by measuring absorbance at 280 nm with a
Nanodrop-1000 microvolume spectrophotometer (Wilmington, DE, USA) using
a calculated extinction coefficient of 15,930 M−1 cm−1 at 280 nm and a
molecular weight of 21.2 kDa (ExPASy ProtParam server)30. Fractions
containing ≥ 0.2 mg/mL LspMrs were combined and desalted using PD10 columns
(GE Healthcare). The tobacco etch virus protease (TEVp) was added to the desalted
protein solution at a final 1/10 molar ratio of TEVp/LspA. TEVp cleavage was
carried out for 18 h at 4 °C. The cleaved and uncleaved LspMrs were separated by
passing the sample through 5 mL Ni-NTA Superflow resin. Cleaved LspMrs was
collected in the flow-through and concentrated to a volume of 1.5 mL using a
15 mL Millipore centrifuge filter with a molecular weight cut-off of 50 kDa. The
concentrated protein sample was loaded onto a HiLoad 16/600 Superdex 200 size-
exclusion column pre-equilibrated with 140 mL Buffer D (50 mM MES/NaOH pH
6.15, 150 mM NaCl, 10%(v/v) glycerol, 0.02%(w/v) LMNG) using a GE Healthcare
ӒKTA Purifier system. Size-exclusion chromatography was performed at 4 °C at a
flow rate of 1 mL/min. Peak fractions with protein concentrations above 0.3 mg/mL
were analyzed by SDS-PAGE and fractions containing pure LspMrs were combined
and concentrated to 14-16 mg/mL using a Millipore centrifuge filter with a
molecular weight cut-off of 50 kDa. The pure protein was divided into 20 μL
aliquots, flash frozen in liquid nitrogen and stored at −70 °C.
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Expression and purification for enzyme assays. The lspA gene was sub-cloned
into a modified pETDuet-1 vector which facilitated higher expression and pur-
ification yields. The recombinant construct was the full length wild-type LspMrs
with an N-terminal MGSS sequence followed by a hexahistidine tag, the linker
sequence SSGR, the TEV protease cleavage site ENLYFQ/G and a AH linker
sequence. Upon cleavage of the N-terminal tag by the TEV protease, the
protein sequence was identical to the one used to obtain crystallographic data.
LspA mutant genes (N52A, N52Q, G54A, G54P, R110A, R110K, D118N,
N133A, N133Q and D136N) were obtained by site-directed mutagenesis of the
wild-type lspA construct in pETDuet. Mutagenesis was performed using the Q5®
Site-Directed Mutagenesis Kit (New England Biolabs) and specific primers are
listed in Supplementary Table 5. The correct mutations were confirmed by
sequencing (Eurofins Genomics). Expression and purification of all LspMrs wild-
type and mutants for enzyme assays were performed as described above with the
following modifications: TALON® Metal Affinity Resin (Clontech) was used for
IMAC purification and the detergent DDM was used for membrane solubilisation
and protein purification. All mutants were further purified by size-exclusion
chromatography with the exception of N133A and N133Q, where expression levels
were low and purification did not proceed beyond the IMAC step.
Crystallisation. Aliquots of purified LspMrs at 14–16 mg/mL in Buffer D were
removed from storage at −70 °C and thawed on ice. A five-fold molar excess of the
antibiotic globomycin or myxovirescin in dimethyl sulfoxide (DMSO) was added
directly to the protein solution and incubated for 30 min on ice to allow binding.
The lipid cubic phase (LCP) was made by mixing two volumes of the
protein–antibiotic solution with three volumes of host lipid monoolein (NuChek)
using two 100 μL gastight glass syringes (Hamilton) connected by a syringe
narrow-bore coupler31,32.
In meso crystallisation trials were set up by dispensing 50 nL boluses of
the protein-laden mesophase onto a silanized 96-well glass crystallization plate
(127.8 mm × 85.5 mm, 1 mm thickness, Marienfeld) to which a 96-well double
stick spacer (77 mm × 112 mm, 140 μm thickness, Saunders Corporation) had been
applied33. Each bolus was covered with 800 nL of precipitant solution using a
Gryphon LCP (Art Robbins) or a Xantus crystallization robot (SIAS)33. Plates were
sealed with a glass cover plate (77 mm × 112 mm, ~170 μm thickness, Marienfeld)
and incubated in a Formulatrix Rock Imager (RockImager 1500, Formulatrix,
USA) at 20 °C.
Best quality crystals of LspMrs with globomycin were obtained using precipitant
solutions containing 47.1%(w/v) polyethylene glycol 1,000, 150 mM Tris/HCl pH
8.0 and 80 mM potassium bromide. The bipyramid-shaped crystals appeared after
4 days at 20 °C and continued to grow to a maximum size of 50 × 50 × 50 μm3 in 15
to 20 days (Supplementary Fig. 2c). Best quality crystals of LspMrs with
myxovirescin were obtained using precipitant solutions containing 100 mM MES/
NaOH pH 6.5, 40%(v/v) PEG400, 400 mM ammonium fluoride and 80 mM
magnesium sulfate. The thin hexagon-shaped crystals appeared after 2–3 days and
reached a maximum size of 80 µm in the longest dimension after 21 days
(Supplementary Fig. 2d). Crystals from the lipid cubic phase were loop-harvested
using MiTeGen cryoloops and snap-cooled in liquid nitrogen directly and without
added cryo-protectant32.
Enzyme assays. The peptidase activity of LspMrs and P. aeruginosa LspA
(LspPae) was quantified in a coupled gel-shift assay developed previously for
LspPae5. The P. aeruginosa lipoprotein pre-proICP and the first two enzymes in
the bacterial lipoprotein processing pathway Lgt and LspA were expressed and
purified, as described5. For FRET assays LspMrs was expressed and purified as
described above and LspPae was expressed and purified as described in a published
protocol5.
Gel-shift activity assay. For time course assays, reactions were set up containing
12 µM pre-proICP, 250 µM DOPG (Avanti Polar Lipids, Inc.) and 1.2 µM Lgt in
Buffer E (50 mM Tris/HCl pH 7.5, 150 mM NaCl, 1 mM DTT, 0.02%(w/v)
LMNG). The assay mixtures were incubated at 37 °C and 200 rpm for 60 min to
allow Lgt catalysed conversion of pre-proICP to the LspA substrate proICP. The
LspA reaction was initiated by adding 0.5 µM LspA directly to the assay mixture.
At timed intervals, 20 µL samples were removed and the reaction was stopped by
adding 10 µL of 4x SDS loading buffer (62.5 mM Tris/HCl pH 6.8, 2.5%(w/v) SDS,
0.002%(w/v) bromophenol blue, 0.5 M β-mercaptoethanol, 10%(v/v) glycerol). To
compare the activity of wild-type and mutant LspMrs, assays were allowed to
proceed for 30 min before being stopped with SDS loading buffer. For dose
response assays, globomycin or myxovirescin were added to the reaction mixture to
a final concentration of 0 to 3.2 mM. The reactions were initiated by adding LspA
and allowed to proceed for 30 min. After the reaction was stopped with SDS buffer,
10 μL aliquots were loaded on precast Mini-PROTEAN® TGXTM gels (Bio-Rad)
and run with Tris/glycine buffer (25 mM Tris/HCl pH 8.0, 250 mM glycine, 0.1%
(w/v) SDS). The gels were stained using InstantBlue™ (Expedeon) Coomassie based
stain and were imaged using a Bio-Rad Gel-Doc imager (Supplementary Fig. 4).
Band intensities of ICP were quantified using Image Lab. Dose-response plots to
determine IC50 values were generated using Prism® 5 software from GraphPad.
FRET activity assays. A FRET based assay was developed using a labelled
lipopeptide substrate (Supplementary Methods, Supplementary Fig. 3b) to directly
monitor the protease activity of LspA. The optimised LspMrs assay buffer included
100 mM Tris/HCl pH 7.8, 150 mM NaCl and 0.09%(w/v) DDM. The
corresponding optimized buffer for LspPae included 100 mM MES/NaOH pH 5.6,
150 mM NaCl and 0.05%(w/v) LMNG. All assays were performed at 37 °C.
Reaction mixtures were prepared by pipetting the FRET lipopeptide substrate
(dissolved in DMSO) directly into assay buffer at a final concentration of 80 µM.
Reaction mixtures were prepared by vortexing (Clifton, cyclone CM-1) for 2 s and
incubated at 37 °C, 800 rpm for 10 to 30 min. Equal volumes of the reaction
mixture were pipetted into 1.5 mL Eppendorf tubes and 0 to 150 µM globomycin or
myxovirescin (in DMSO) added. For dose-response assays, the final DMSO
concentration in all reactions was 10%(v/v). Reaction mixtures were pipetted into
wells of a 96- (Thermo Scientific) or a 384-well plate (4titude®) and incubated for
10 min at 37 °C in a SpectraMax M3 or a SpectraMax M5e plate reader (Molecular
devices) prior to starting the assay. Assays were initiated by adding enzyme to a
final concentration in the range 10–300 nM. Total reaction mixture volume was
50 μL. Reactions were monitored by fluorescence (Ex/Em, 320 nm/420 nm) for 30
to 60 min at 37 °C. Initial rates were calculated from the fluorescence intensity
versus time progress curves (Supplementary Figs. 5 and 6). Occasionally, lag
periods in the progress curves were observed (Supplementary Discussion). In such
cases, initial rates were calculated after the lag period had passed (typically
1–5 min) and a steady rate had been established. Dose-response plots to determine
IC50 values were generated using Prism® 5 software from GraphPad.
It was possible to convert units of fluorescence change into moles of substrate
consumed or products formed because pure products of LspA action on Abz-
LALAGC*SS-nY-NH2 had been synthesized and were available. These were used to
create a standard curve of fluorescence versus moles of the two products in
equimolar amounts and to calculate specific activity values. Inner filter effect
correction was not required in the current study because absorbance values of
samples used for FRET measurements never exceeded 0.06 and 0.02 at 320 and
420 nm, respectively, and the sum of absorbance at the excitation and emission
wavelengths did not exceed 0.0834. A calibration curve generated using the purified
FRET products showed that fluorescence was linear at the substrate
concentrations used.
LspMrs proICP docking. Docking of LspMrs and prolipoprotein proICP was per-
formed with HADDOCK (version 2.2 webserver)35. The model of prolipoprotein
proICP docked into LspPae5 and the LspMrs structure (6RYO) were used as docking
models. In a text editor (Notepad, Microsoft), the atom record labels for the acyl
chains were relabelled HETATM and the lipobox cysteine were renamed CYC. The
files were uploaded to the HADDOCK webserver for docking. In HADDOCK,
LspMrs residues 52-57 and 68-154, corresponding to H1, H2 and H3 and the EL were
defined as active. Likewise, ProICP residues 1-22, corresponding to the signal peptide,
were defined as active. All other residues were defined as passive. The HADDOCK
distance restraints TBL file was uploaded. The target distance was set to 1.8 Å. The
upper and lower distance margins were set to 0.1 Å. The top nine docking solutions
(lowest HADDOCK scores) were downloaded and the docking solutions inspected
manually in PyMOL. The top solution made the most sense by eye and was chosen as
the model for inclusion in Supplementary Fig. 9.
Globomycin production. Bacterial strain and culture conditions. Streptomyces
hagronensis strain 360, NRRL 1506436 was used to produce globomycin. Spores
were generated on ISP2 medium37 agar plates at 30 °C for 10–14 days, and were
preserved in 20% glycerol at −80 °C. For globomycin production a 1% spore
inoculum was prepared in SHG-V (1% glycerol, 1% Bacto™ peptone, 1% Bacto™
yeast extract, distilled water, pH 7.0)36 and was cultivated at 28 °C, 220 rpm for
3 days. It was further inoculated (5%) into SOYF6 medium (4.5% glycerol, 2%
Bacto™ beef extract, 1% soy flour (Hensel), 0.2% CaCO3, distilled water, pH 6.0
adjusted with KOH) (adapted from20) and incubated at 26 °C, 220 rpm for 5 days.
In all, 2% amberlite XAD-16 was added after cultivation was complete.
Extraction and purification. The culture broth was centrifuged at
8300 × g for 10 min at RT and DCM was added to the cell pellet. The DCM extract
was concentrated and washed once with 500 mL 0.05M HCl and 2% NaHCO3 and
twice with 200 mL of brine followed by drying with Na2SO420. The organic phase
was dried, fractionated on silica by flash chromatography using a linear gradient
from 0 to 100% B using (A) hexane+ 0.1% formic acid (FA) and (B) 80% EtOAc,
20% MeOH+ 0.1% FA. Fractions containing globomycin were subjected to flash
chromatography again this time using (A) EtOAc+ 0.1% FA and (B) MeOH+
0.1% FA with a linear gradient from 1% to 20% B. Obtained samples were purified
using preparative LC-MS (Dionex Ultimate 3000 coupled with Bruker High
capacity trap mass spectrometer). Separation of the sample was carried out on a
5 μm EVO C18 100 Å LC column (250 mm × 10.0 mm, Kinetex) using a linear
gradient (5–95% B in 31 min) from (A) ultrapure water+ 0.1% FA to (B)
acetonitrile+ 0.1% FA and on a 5 μm Biphenyl 100 Å LC column (250 mm ×
10.0 mm, Kinetex) a linear gradient of 42–43% B in 22 min at a flow rate of
5 mL/min and 45 °C.
Quantitation, HRMS and NMR structural analysis. An UHPLC system
(UltiMate 3000 LC (Dionex) with 1.7 μm Acquity UPLC BEH C-18 Column
(2.1 mm × 100 mm) coupled with an electrospray ionization (ESI) source linked to
an amaZon speed MS (Bruker Daltonics; 3D ion trap)) was used for quantification.
Separation of a 1 μL sample was achieved using a linear gradient (56–57% B in
7.5 min) from (A) ultrapure water+ 0.1% FA to (B) acetonitrile+ 0.1% FA at a
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flow rate of 0.600 mL/min at 45 °C. For precise mass determination (HRMS)
samples were measured on a UHPLC coupled to maXis 4 G MS system (Bruker
Daltonics; Q-ToF). Separation of a 1 μL sample, with 1.7 μm Acquity UPLC BEH
C-18 Column (2.1 mm × 50mm), was achieved using a linear gradient (5-95% B in
6 min) from (A) ultrapure water+ 0.1% FA to (B) acetonitrile+ 0.1% FA at a flow
rate of 0.600 mL/min at 45 °C. Absorption spectra (200-600 nm) were recorded by
a diode array detector. Mass spectra were acquired in centroid mode ranging from
200 to 2000 m/z (amaZon) or from 150 to 2500 m/z (maXis 4 G) in positive
ionization mode with auto MS-MS fragmentations. NMR spectra (1 H, 2D) were
recorded on a Bruker Ascend 700 spectrometer with a 5 mm TXI cryoprobe (1 H at
700MHz, 13 C at 175MHz) at ambient temperature using standard pulse
programs and results compared to the literature38. Final purity was estimated at
>95% by LCMS, HRMS and NMR.
Myxovirescin production. Myxovirescin was produced by growing Myxococcus
virescens strain Mx v48 in a 70 L fermenter, essentially as described by Gerth et al.39
with the following modification: the medium was supplemented with 185 mL
amberlite XAD-16 resin (Sigma Aldrich). Elution from the resin was performed
using 800 mL methanol. After evaporating off the methanol, the dry material was
extracted three times with ethyl acetate. The extract was dried using sodium sulfate
followed by filtration and evaporation of the solvent. After resolubilisation in
200 mL methanol, a liquid-liquid extraction using 3 × 200 mL hexane was per-
formed. The methanol was again evaporated yielding 750 mg of dry material. The
extract was further separated using a column (70 mm × 600 mm) prepacked with
Sephadex LH20 (Sigma Aldrich). The flow rate was 9 mL per min using methanol
as the mobile phase. Fractions containing myxovirescin were pooled, dried, and the
weight of the extract was determined to be 146 mg. Further purification was per-
formed using RP-HPLC on a Nucleodur 100 EC C18 column (10 µm, 250 mm ×
21mm) and a flow rate of 20 mL per min with detection at 254 nm. The mobile
phase consisted of solvent A (methanol:water, 1:1) and solvent B (methanol). A
gradient of 30 min was applied with a steady increase of solvent B from 55% to
62%. The final yield of purified myxovirescin was 73 mg.
Diffraction data collection and processing. X-ray diffraction experiments were
performed at the protein crystallography beamline X06SA-PXI, Swiss Light Source
(SLS), Villigen-PSI, Switzerland. Data were collected at 100 K with a 10 × 10 μm2
microfocused X-ray beam at 13.476 keV (0.92003 Å) for LspMrs-globomycin and
at 12.398 keV (1 Å) for LspMrs-myxovirescin using SLS data acquisition software
suites (DA+)40. Continuous grid-scans were used to locate crystals in cryogenically
cooled mesophase samples41. Data were collected in steps of 0.2° at 0.1 s per step
using the EIGER 16M detector operated in continuous/shutterless data
collection mode.
A 90° data set for LspMrs-globomycin, collected at a flux of 1.4 × 1012 photons
s−1, was processed using autoPROC/STARANISO42,43, scaled and merged with
XSCALE44. The crystals, which belonged to space group P3221, diffracted to 1.92 Å
resolution with an ellipsoidal completeness of 62.5%, a CC1/2 of 0.47 and an I/σ of
1.8 in the highest resolution shell. The same flux was used for data collection with
LspMrs-myxovirescin crystals. Two data sets of 60° and 90° for LspMrs-
myxovirescin were processed with XDS and scaled and merged with XSCALE. The
crystals, which belonged to space group P6122, diffracted to 2.30 Å resolution with
a completeness of 100%, a CC1/2 of 0.22 and an I/σ of 0.9 in the highest resolution
shell. Data collection and processing statistics are provided in Table 2. Electron
density defining the bound antibiotics is shown in Supplementary Fig. 11.
Structure solution and refinement. Molecular replacement (MR) was employed
for phasing using a poly-Ala structure of 5DIR5 as search model for LspMrs-
globomycin and a solution was obtained using Phaser45. The MR solution was
submitted together with the LspMrs sequence to PHENIX-AutoBuild46 for initial
model building. The 155 residues in LspMrs-globomycin were built and the
structure was iteratively refined to Rwork/Rfree factors of 0.25/0.28 using Coot47 and
Phenix.refine48. The structure of the LspMrs-globomycin was used as search model
for LspMrs-myxovirescin and a solution was obtained using Phaser. The 164
residues in LspMrs were built and the structure was refined to Rwork/Rfree factors of
0.25/0.28 using Coot and Phenix.refine, respectively. Refinement statistics are
reported in Table 2. Figures of molecular structures were generated with PyMOL49.
Data availability
Data supporting the findings of this paper are available from the corresponding author
upon reasonable request. A reporting summary for this Article is available as a
Supplementary Information file. The structure and structure factors for LspMrs, LspA
from S. aureus (MRSA), in complex with globomycin and myxovirescin A1 were
deposited into the Protein Data Bank under accession codes 6RYO and 6RYP,
respectively. The source data underlying Fig. 2 and Supplementary Figs. 1, 4, 5, 6a–d, 8,
18 and 19a are provided as a Source Data file.
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